Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington. Show more

Location: 22722 29th Dr. SE, Bothell, WA, 98021, United States | Website: https://www.achievelifesciences.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

115.3M

52 Wk Range

$1.84 - $5.31

Previous Close

$2.33

Open

$2.33

Volume

355,579

Day Range

$2.25 - $2.34

Enterprise Value

65.1M

Cash

23.25M

Avg Qtr Burn

-8.893M

Insider Ownership

9.69%

Institutional Own.

41.59%

Qtr Updated

03/31/25